Junmao Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junmao Li has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Min Yao
Jiangxi University of Chinese Medicine, Nanchang, 330006, PR China
6 shared publications- Yulin Feng
jiangxi University of Chinese Medicine, National Pharmaceutical Engineering Center for Solid Preparations of Chinese Herbal Medicine, Nanchang 330006, China
6 shared publications Mingzhen He
Jiangxi University of Chinese Medicine, Nanchang, 330006, PR China
5 shared publicationsYushun Cui
Jiangxi University of Chinese Medicine, Nanchang, 330006, PR China
5 shared publicationsHui Ouyang
jiangxi University of Chinese Medicine, National Pharmaceutical Engineering Center for Solid Preparations of Chinese Herbal Medicine, Nanchang 330006, China
3 shared publicationsZhaojun Wang
Jiangxi University of Chinese Medicine, Nanchang, 330006, PR China
3 shared publications
Latest Publications
- Open Access
Bioactive Fraction LCS2 from Litchi (Litchi chinensisSonn.) Seed By-Product Attenuates LPS-Induced Acute Prostatic Inflammatory Injury via Modulating NF-κB and MAPK Signaling Pathways
Litchi seed is a major by-product of the litchi processing industry, rich in polyphenols and flavonoids with documented anti-inflammatory properties. Prostatic inflammatory injury remains a prevalent male health concern, and dietary intervention with natural bioactive components represents a promising strategy for prostate health maintenance. This study investigated the protective efficacy of LCS2, a bioactive fraction isolated from litchi seed by-product, against lipopolysaccharide (LPS)-induced prostatic inflammatory injury in rats and explored its underlying mechanisms. LCS2 was obtained via extraction, purification, and activity screening, and its chemical profile was characterized by ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF-MS/MS). Its anti-inflammatory activity and pathway regulatory effects were evaluated in LPS-stimulated RAW264.7 macrophages and further verified in a rat model of LPS-induced acute prostatic inflammation. A total of 26 compounds, mainly flavonoids, polyphenols, and tannins, were tentatively identified in LCS2. In vitro, LCS2 pretreatment with LCS2 at concentrations up to 40 μg/mL dose-dependently suppressed LPS-induced overproduction of nitric oxide (NO) and reactive oxygen species (ROS), reduced pro-inflammatory cytokine mRNA levels, and downregulated iNOS and COX-2 protein expression. In vivo, 7-day dietary pretreatment with LCS2 at doses up to 100 mg/kg ameliorated prostate histopathological injury, reduced peripheral inflammatory cell counts, and decreased inflammatory mediator levels in serum and prostate tissue by inhibiting NF-κB and MAPK pathway activation. These findings support the high-value valorization of litchi seed by-product and highlight the potential of LCS2 for further development as a bioactive component for prostate health applications.
Open AccessBioactive Fraction LCS2 from Litchi (Litchi chinensisSonn.) Seed By-Product Attenuates LPS-Induced Acute Prostatic Inflammatory Injury via Modulating NF-κB and MAPK Signaling Pathways
Litchi seed is a major by-product of the litchi processing industry, rich in polyphenols and flavonoids with documented anti-inflammatory properties. Prostatic inflammatory injury remains a prevalent male health concern, and dietary intervention with natural bioactive components represents a promising strategy for prostate health maintenance. This study investigated the protective efficacy of LCS2, a bioactive fraction isolated from litchi seed by-product, against lipopolysaccharide (LPS)-induced prostatic inflammatory injury in rats and explored its underlying mechanisms. LCS2 was obtained via extraction, purification, and activity screening, and its chemical profile was characterized by ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF-MS/MS). Its anti-inflammatory activity and pathway regulatory effects were evaluated in LPS-stimulated RAW264.7 macrophages and further verified in a rat model of LPS-induced acute prostatic inflammation. A total of 26 compounds, mainly flavonoids, polyphenols, and tannins, were tentatively identified in LCS2. In vitro, LCS2 pretreatment with LCS2 at concentrations up to 40 μg/mL dose-dependently suppressed LPS-induced overproduction of nitric oxide (NO) and reactive oxygen species (ROS), reduced pro-inflammatory cytokine mRNA levels, and downregulated iNOS and COX-2 protein expression. In vivo, 7-day dietary pretreatment with LCS2 at doses up to 100 mg/kg ameliorated prostate histopathological injury, reduced peripheral inflammatory cell counts, and decreased inflammatory mediator levels in serum and prostate tissue by inhibiting NF-κB and MAPK pathway activation. These findings support the high-value valorization of litchi seed by-product and highlight the potential of LCS2 for further development as a bioactive component for prostate health applications.
- 30 May 2026
- Published by Elsevier in Journal of Ethnopharmacology
- p. 121913
Corrigendum to “Therapeutic effects of Ainsliaea fragrans champ. and its active compounds on cervicitis: An integrated approach combining metabolomics, network pharmacology, and experimental validation” [J. Ethnopharmacol. (2025) 359 121117]
- 30 May 2026
- Published by Elsevier in Journal of Ethnopharmacology
- p. 121913
Corrigendum to “Therapeutic effects of Ainsliaea fragrans champ. and its active compounds on cervicitis: An integrated approach combining metabolomics, network pharmacology, and experimental validation” [J. Ethnopharmacol. (2025) 359 121117]
- 29 April 2025
- Published by Elsevier in Fitoterapia
- Vol. 184, 106579
Guaiane sesquiterpenoid—Glucozaluzanin C from Ainsliaea fragrans Champ. targets TLR4/p65 to regulate NF-κB/MAPK pathway, alleviating sepsis-induced acute liver injury
- 29 April 2025
- Published by Elsevier in Fitoterapia
- Vol. 184, 106579
Guaiane sesquiterpenoid—Glucozaluzanin C from Ainsliaea fragrans Champ. targets TLR4/p65 to regulate NF-κB/MAPK pathway, alleviating sepsis-induced acute liver injury
- 27 July 2024
- Published by Elsevier in Journal of Chromatography B
- Vol. 1244, 124259
Characterization of chemical constituents and metabolites in rat plasma after oral administration of Ainsliaea fragrans Champ by using UHPLC-QTOF-MS/MS
- 27 July 2024
- Published by Elsevier in Journal of Chromatography B
- Vol. 1244, 124259
Characterization of chemical constituents and metabolites in rat plasma after oral administration of Ainsliaea fragrans Champ by using UHPLC-QTOF-MS/MS
- Open Access
- 26 November 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-17
The Regulatory Network of Gastric Cancer Pathogenesis and Its Potential Therapeutic Active Ingredients of Traditional Chinese Medicine Based on Bioinformatics, Molecular Docking, and Molecular Dynamics Simulation
Objective. This study aims to investigate the functional gene network in gastric carcinogenesis by using bioinformatics; besides, the diagnostic utility of key genes and potential active ingredients of traditional Chinese medicine (TCM) for treatment in gastric cancer have been explored. Methods. The Cancer Genome Atlas and Gene Expression Omnibus databases have been applied to analyze the differentially expressed genes (DEGs) between gastric cancer and normal gastric tissues. Then, the DEGs underwent Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses using the Metascape database. The STRING database and the Cytoscape software were utilized for the protein-protein interaction network of DEGs and hub genes screening. Furthermore, survival and expression analyses of hub genes were conducted using Gene Expression Profiling Interactive Analysis and Human Protein Atlas databases. By using the Comparative Toxicogenomics Database, the hub genes interconnected with active ingredients of TCM were analyzed to provide potential information for the treatment of gastric cancer. After the molecular docking of the active ingredients of TCM to specific hub gene receptor proteins, the molecular dynamics simulation GROMACS was applied to validate the conformation of the strongest binding ability in the molecular docking. Results. A total of 291 significant DEGs were found, from which 12 hub genes were screened out. Among these hub genes, the expressions of five hub genes including COL1A1, COL5A2, MMP12, SERPINE1, and VCAN were significantly correlated with the overall survival. Furthermore, four potential therapeutic active ingredients of TCM were acquired, including quercetin, resveratrol, emodin, and schizandrin B. In addition, the molecular docking results exhibited that the active ingredients of TCM formed stable binding with the hub gene targets. SERPINE1 (3UT3)-Emodin and COL1A1 (7DV6)-Quercetin were subjected to molecular dynamics simulations as conformations of continuing research significance, and both were found to be stably bound as a result of the interaction of van der Waals potentials, electrostatic, and hydrogen bonding. Conclusion. Our findings may provide novel insights and references for the screening of biomarkers, the prognostic evaluation, and the identification of potential active ingredients of TCM for gastric cancer treatment.
- 26 November 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-17
Open AccessThe Regulatory Network of Gastric Cancer Pathogenesis and Its Potential Therapeutic Active Ingredients of Traditional Chinese Medicine Based on Bioinformatics, Molecular Docking, and Molecular Dynamics Simulation
Objective. This study aims to investigate the functional gene network in gastric carcinogenesis by using bioinformatics; besides, the diagnostic utility of key genes and potential active ingredients of traditional Chinese medicine (TCM) for treatment in gastric cancer have been explored. Methods. The Cancer Genome Atlas and Gene Expression Omnibus databases have been applied to analyze the differentially expressed genes (DEGs) between gastric cancer and normal gastric tissues. Then, the DEGs underwent Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses using the Metascape database. The STRING database and the Cytoscape software were utilized for the protein-protein interaction network of DEGs and hub genes screening. Furthermore, survival and expression analyses of hub genes were conducted using Gene Expression Profiling Interactive Analysis and Human Protein Atlas databases. By using the Comparative Toxicogenomics Database, the hub genes interconnected with active ingredients of TCM were analyzed to provide potential information for the treatment of gastric cancer. After the molecular docking of the active ingredients of TCM to specific hub gene receptor proteins, the molecular dynamics simulation GROMACS was applied to validate the conformation of the strongest binding ability in the molecular docking. Results. A total of 291 significant DEGs were found, from which 12 hub genes were screened out. Among these hub genes, the expressions of five hub genes including COL1A1, COL5A2, MMP12, SERPINE1, and VCAN were significantly correlated with the overall survival. Furthermore, four potential therapeutic active ingredients of TCM were acquired, including quercetin, resveratrol, emodin, and schizandrin B. In addition, the molecular docking results exhibited that the active ingredients of TCM formed stable binding with the hub gene targets. SERPINE1 (3UT3)-Emodin and COL1A1 (7DV6)-Quercetin were subjected to molecular dynamics simulations as conformations of continuing research significance, and both were found to be stably bound as a result of the interaction of van der Waals potentials, electrostatic, and hydrogen bonding. Conclusion. Our findings may provide novel insights and references for the screening of biomarkers, the prognostic evaluation, and the identification of potential active ingredients of TCM for gastric cancer treatment.
- 1 June 2021
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 31 (3) , 322-329
Protective Activity of Cubebin from Syringa oblata Against CCl4-Induced Hepatic Damage in Mice
- 1 June 2021
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 31 (3) , 322-329
Protective Activity of Cubebin from Syringa oblata Against CCl4-Induced Hepatic Damage in Mice